Weekend News: Business, Finance and Innovations in Biotech and Pharma Industries


Check out the happenings of biotech and pharma industries during the weekends;

AbbVie’s Humira Gained FDA Approval for Eye Disease, Uveitis

AbbVie’s Humira (adalimumab) has been approved by the US FDA for the treatment of noninfectious, intermediate, posterior and panuveitis. It has also received the approval of European Commission for the treatment of adult patients in European Union suffering from noninfectious, intermediate, posterior and panuveitis who had responded inadequately to corticosteroids.

Humira targets and assists in blocking the specific source of inflammation, tumor necrosis factor (TNF) which plays part in uveitis.

The FDA approval is based on results obtained from two pivotal Phase III studies, VISUAL-I and VISUAL-II. In these studies, it was observed that Humira significantly lowered the risk of treatment failure (a combination of uveitic flare and decrease in visual acuity) compared to placebo in adult patients with active and controlled non-infectious intermediate, posterior and panuveitis.

We are pleased to provide patients with the first FDA-approved non-corticosteroid treatment option for certain types of uveitis, an eye disease that can flare and impact vision,” said Mike Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. “These approvals reflect our ongoing focus on continuing to innovate with Humira to address critical unmet needs of patients living with serious immune-mediated diseases“.


Leo Receive the Rights of Astrazeneca Two Dermatology Drugs

Astrazeneca licensed its two dermatology drugs-Tralokinumab, Brodalumab to Leo Pharma for the development these two investigational candidate. Leo Pharma will pay $115 million as upfront payment to Astrazeneca and $1 billion in milestones.

Astrazeneca will be involved in the manufacture and supply of Tralokinumab to Leo Pharma, retaining rights to the drug candidate in diseases outside dermatology like severe asthma. Tralokinumab is an anti-interleukin-13 (IL-13) monoclonal antibody. Its Phase IIb trial is completed to treat atopic dermatitis patients.

Brodalumab, an IL-17 receptor monoclonal antibody is currently under review  for patients with moderate-to-severe plaque psoriasis and psoriatic arthritis.


Gilead and Massachusetts Concluded to Rebates for hep C drugs

The Commonwealth of Massachusetts has finally reached a deal with Gilead Sciences for Gilead’s hepatitis C drugs- Harvoni and Sovaldi, after threats to sue the company over its high priced hepatitis C treatments.

The deal will begin on August 1st.

This rebate agreement will expand access to much-needed medication for people suffering from Hepatitis C, and it will save millions in taxpayer dollars“. -Massachusetts Attorney General Maura Healey.

Featured image credit: Drops of rain on glass. © darkbird (Stock Photo ID: 84115811)

Leave a reply

Your email address will not be published. Required fields are marked *